Adlai Nortye Ltd banner

Intrinsic Value

Not Available for N2U0

There is not enough data to reliably calculate the intrinsic value for Adlai Nortye Ltd.

Do our valuations actually work? See backtest results .

Alternatives to N2U0

Fundamental Analysis

What Adlai Nortye Does

Biotechnology Health Care

Adlai Nortye Ltd. is a clinical-stage biotechnology company that develops cancer medicines, with a focus on drugs that target tumor growth signals and help the immune system attack cancer. Its work is centered on discovering, testing, and advancing experimental therapies through clinical trials rather than selling approved medicines at scale.

Headquarters
Cayman Islands KY
Employees
109
IPO date
Sep 29, 2023
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Ownership

Adlai Nortye insiders are selling more than usual

Insider trading · Last trade on Sep 30, 2026

Sold $331.4k 3 insiders
Bought $0 Nobody bought
Trades by date
Open insider trading

Insiders sell for many reasons, such as taxes or planned sales; purchases are rarer.

Continue N2U0 Research

Decided on Adlai Nortye? Get an email when N2U0 reaches the price you’d buy at. Free with an account.

Other Adlai Nortye listings

Back to Top